EpistrySign in
LimitedMetadata only — full assessment not yet run

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies

Ole Jakob Storebø, Nadia Pedersen, E Ramstad, Maja Laerke Kielsholm, Signe Sofie Nielsen, Helle B. Krogh, Carlos Renato Moreira Maia, Frederik L Magnusson, Mathilde Holmskov, Trine Gerner, Maria Skoog, Susanne Rosendal, Camilla Groth, Donna Gillies, Kirsten Rasmussen, Dorothy Gauci, Morris Zwi, Richard Kirubakaran, Sasja Jul Håkonsen, Lise Aagaard, Erik Simonsen, Christian Gluud · Cochrane Database of Systematic Reviews · 2018

DOI 10.1002/14651858.cd012069.pub2

Why this label

  • Metadata only — full assessment not yet run.

The Paper Scorecard

  • Standingclear
    • No retraction on record (OpenAlex metadata as of 2026-08-23).
  • Designjournal article
    • Journal article (Cochrane Database of Systematic Reviews). Study design detail comes from the methodology read, not metadata.
  • Executionnot assessed
    • Metadata only — full assessment not yet run.
  • Corroborationhighly cited
    • Cited by 321 works (OpenAlex citation count).
  • Provenanceidentified
    • Published in Cochrane Database of Systematic Reviews.
    • Publisher: Elsevier BV.
    • ISSN 1361-6137.
    • The journal is not listed in DOAJ.
    • Open-access status: bronze.
Assessed by Epistry · metadata as of August 23, 2026
Methylphenidate for attention deficit hyperactivity disorder (ADHD) i… — Epistry